US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

VanEck Biotech ETF

237.45

-1.2830-0.54%

Post-market: 237.580.1269+0.05%19:30 EDT

Volume:11.62K

Turnover:2.76M

Market Cap:474.08M

PE:- -

High:238.35

Open:238.12

Low:236.49

Close:238.74

52wk High:246.55

52wk Low:171.63

Shares:2.00M

Float Shares:2.00M

Volume Ratio:0.98

T/O Rate:0.58%

Dividend:0.95

Dividend Rate:0.40%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Amgen Rises After Autoimmune Drug Meets Late-Stage Trial Goal

Amgen Says Dazodalibep Meets Primary Endpoint in Phase 3 Sjögren's Disease Trial

Amgen Shares up 3% After Co's Autoimmune Disease Drug Succeeds in Late-Stage Trial

THOMSON REUTERS

Amgen Says Phase 3 Trial Shows Dazodalibep Cuts Systemic Disease Activity in Sjögren’s Disease

Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR by -42.7% at Week 13 in AMKD with Modest Proteinuria

Amgen Announces Positive Topline Phase 3 Results for Dazodalibep in Moderate-to-Severe Systemic SjÖGren's Disease

THOMSON REUTERS

Amgen: Dazodalibep Showed Statistically Significant & Clinically Meaningful Improvement in Systemic Disease Activity

THOMSON REUTERS

Amgen: Phase 3 Oasiz 303 Study of Dazodalibep in Moderate-to-Severe Symptomatic SjÖGren’s Disease Expected to Complete in Q4 2026

THOMSON REUTERS

AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib

Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial

MT Newswires Live

Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015

Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study

Vertex Says Phase 2b Amplified Study Shows Inaxaplin Cuts Proteinuria in APOL1-Mediated Kidney Disease Patients with Modest Proteinuria

Vertex Pharmaceuticals Incorporated - Inaxaplin Reduces Uacr by -42.7% at Week 13 in Amkd with Modest Proteinuria

THOMSON REUTERS

Vertex Pharmaceuticals Incorporated - Inaxaplin Generally Safe and Well Tolerated in Both Amkd Cohorts

THOMSON REUTERS

Vertex Announces Positive Results from Phase 2B Amplified Study of Inaxaplin in Additional Populations of People with Apol1-Mediated Kidney Disease (Amkd) and Completion of Enrollment in the Phase 2/3 Amplitude Trial

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Invivyd (IVVD) and Humacyte (HUMA)

Sino Biopharmaceutical Stock Slips 1.4% in Hong Kong, Underperforms Competitors

Nvidia, QIA-Backed Iambic Therapeutics Files for US IPO as Biotech Boom Rolls On

Moderna Inc. Stock Climbs 12.3%, Outperforms Peers

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/BBH/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BBH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBH\",,,,,undefined,":{"symbol":"BBH","market":"US","secType":"STK","nameCN":"VanEck Biotech ETF","latestPrice":237.4531,"timestamp":1790971200000,"preClose":238.7361,"halted":0,"volume":11617,"hourTrading":{"tag":"盘后","latestPrice":237.58,"preClose":237.4531,"latestTime":"19:30 EDT","volume":23,"amount":5462.9441,"timestamp":1790983804584,"change":0.1269,"changeRate":0.000534,"amplitude":0},"delay":0,"changeRate":-0.0053741348710982005,"floatShares":1996503,"shares":1996503,"eps":0,"marketStatus":"Market Closed","change":-1.283,"latestTime":"10-02 16:00:00 EDT","open":238.115,"high":238.345,"low":236.49,"amount":2757782.5154899997,"amplitude":0.00777,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":238.7361,"sharesOutstanding":1976503,"nav":237.39591,"aum":476335613.78,"dividendRate":0.004017,"bidAskSpread":0.001118,"preHourTrading":{"tag":"盘前","latestPrice":238.7361,"preClose":238.7361,"latestTime":"08:20 EDT","volume":1,"amount":238.7361,"timestamp":1790943636127,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":237.58,"preClose":237.4531,"latestTime":"19:30 EDT","volume":23,"amount":5462.9441,"timestamp":1790983804584,"change":0.1269,"changeRate":0.000534,"amplitude":0},"volumeRatio":0.9753333052126362,"impliedVol":0.1958,"impliedVolPercentile":0.4661},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBH\",,,,,undefined,":{"symbol":"BBH","floatShares":1996503,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.9753333052126362,"shares":1996503,"dividePrice":0.9538,"high":238.345,"amplitude":0.00777,"preClose":238.7361,"low":236.49,"week52Low":171.63,"pbRate":"--","week52High":246.55,"institutionHeld":0,"latestPrice":237.4531,"eps":0,"divideRate":0.004017,"volume":11617,"delay":0,"ttmEps":0,"open":238.115,"prevYearClose":189.2649,"prevWeekClose":245.36,"prevMonthClose":244.575,"prevQuarterClose":244.575,"fiveDayClose":245.36,"twentyDayClose":243.7291,"sixtyDayClose":210.1281},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"BBH","amount":0.9565,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"VanEck Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-12-23","symbol":"BBH","amount":1.2517,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"VanEck Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-24","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-24"},{"date":"2023-12-18","symbol":"BBH","amount":0.7127,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"VanEck Biotech ETF","recordDate":"2023-12-22","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-22"},{"market":"US","date":"2022-12-19","symbol":"BBH","amount":0.7488,"defaultRemindTime":1671460200000,"name":"VanEck Biotech ETF","recordDate":"2022-12-23","payableDate":"2022-12-20","currency":"USD","type":"dividend","dateTimestamp":1671426000000},{"market":"US","date":"2021-12-20","symbol":"BBH","amount":0.3972,"defaultRemindTime":1640010600000,"name":"VanEck Vectors Biotech ETF","recordDate":"2021-12-27","payableDate":"2021-12-21","currency":"USD","type":"dividend","dateTimestamp":1639976400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBH\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-19","recordDate":"2016-12-21","paymentDate":"2016-12-23","value":0.327,"currency":"USD"},{"executeDate":"2018-12-20","recordDate":"2018-12-21","paymentDate":"2018-12-27","value":0.006,"currency":"USD"},{"executeDate":"2019-12-23","recordDate":"2019-12-24","paymentDate":"2019-12-30","value":0.4724,"currency":"USD"},{"executeDate":"2020-12-21","recordDate":"2020-12-22","paymentDate":"2020-12-28","value":0.6079,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-27","value":0.3972,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBH\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669470171","title":"Amgen Rises After Autoimmune Drug Meets Late-Stage Trial Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2669470171","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669470171?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:48","pubTimestamp":1790084894,"startTime":"0","endTime":"0","summary":"BUZZ-Amgen rises after autoimmune drug meets late-stage trial goal** Shares of drugmaker AmgenAMGN.Orise 2.4% to $402.69** Co says its experimental drug, dazodalibep, for Sjogren's diseasemet the main goalof reducing disease activity in a late-stage trial** Sjogren's disease is an autoimmune disorder that causes dryness of the eyes, mouth and other parts of the body, along with fatigue and chronic pain** Drug showed a statistically significant and clinically meaningful improvement at week 48; most side effects were mild to moderate** Co plans to present detailed results at an upcoming medical meeting** Including session's move, AMGN up 23.1% YTD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nL4N45E0WO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242646821.SGD","IE0009355771.USD","IE00B2B36J28.USD","LU0058720904.USD","IE00BFTCPJ56.SGD","BBH","LU0109394709.USD","LU0868494617.USD","BK4566","LU1057294990.SGD","LU0122379950.USD","LU0889565916.HKD","BK4599","BK4534","LU2112291526.USD","BK4588","IE0002141913.USD","IE00BJJMRZ35.SGD","PJP","PBE","IBB","SG9999001440.SGD","BK4585","LU1983299246.USD","BK4139","BK4533","TBXU","IBBQ","LU0289739699.SGD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","AMGN","LU1571399168.USD","BK4581","LU2468319806.SGD","LU0320765992.SGD","LU1023059063.AUD","BIB","LU2089984988.USD","LU2242652126.USD","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669147050","title":"Amgen Says Dazodalibep Meets Primary Endpoint in Phase 3 Sjögren's Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669147050","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669147050?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:45","pubTimestamp":1790084715,"startTime":"0","endTime":"0","summary":"Sept 22 (Reuters) - Amgen Inc::*AMGEN: PHASE 3 OASIZ 303 STUDY OF DAZODALIBEP IN MODERATE-TO-SEVERE SYMPTOMATIC SJGREN’S DISEASE EXPECTED TO COMPLETE IN Q4 2026*AMGEN: DAZODALIBEP MEETS PRIMARY ENDPOI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nRSDcc0x9T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBE","LU1061106388.HKD","LU0122379950.USD","IE00BJJMRZ35.SGD","BIB","LU0320765992.SGD","LU2242646821.SGD","LU2242652126.USD","LU0868494617.USD","LU2468319806.SGD","LU1023059063.AUD","AMGN","BBH","LU0109394709.USD","LU2089984988.USD","LU0289739699.SGD","LU1057294990.SGD","BK4566","LU1571399168.USD","PJP","IE00B4R5TH58.HKD","IE0009355771.USD","IE00BFTCPJ56.SGD","SG9999001440.SGD","IE00B2B36J28.USD","BK4585","LU1983299246.USD","BK4599","IBB","BK4533","IE0002141913.USD","BK4139","LU0889565916.HKD","TBXU","LU2112291526.USD","BK4534","BK4588","BK4581","LU0058720904.USD","IE00BJT1NW94.SGD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669147177","title":"Amgen Shares up 3% After Co's Autoimmune Disease Drug Succeeds in Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669147177","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669147177?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:36","pubTimestamp":1790084178,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nL4N45E0VV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4566","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4534","LU0889565916.HKD","LU2468319806.SGD","LU2112291526.USD","BBH","LU1571399168.USD","LU0320765992.SGD","IE00BFTCPJ56.SGD","AMGN","PBE","BK4585","LU1983299246.USD","SG9999001440.SGD","IBB","LU0289739699.SGD","IE00BJJMRZ35.SGD","IE0002141913.USD","IBBQ","TBXU","LU0868494617.USD","LU1057294990.SGD","LU2089984988.USD","LU0058720904.USD","LU0109394709.USD","LU0122379950.USD","BK4533","PJP","LU1061106388.HKD","LU2242646821.SGD","IE00BJT1NW94.SGD","BIB","BK4581","BK4599","BK4588","BK4139","LU1023059063.AUD","IE0009355771.USD","LU2242652126.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669414223","title":"Amgen Says Phase 3 Trial Shows Dazodalibep Cuts Systemic Disease Activity in Sjögren’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2669414223","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669414223?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:04","pubTimestamp":1790082271,"startTime":"0","endTime":"0","summary":"Amgen says Phase 3 trial shows dazodalibep cuts systemic disease activity in Sjgren’s diseaseAmgen reported positive topline Phase 3 results for dazodalibep in adults with moderate-to-severe systemic ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL63L4Jz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","TBXU","IE00B4R5TH58.HKD","LU1061106388.HKD","IE0009355771.USD","LU2468319806.SGD","LU1057294990.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00B2B36J28.USD","LU0122379950.USD","LU0889565916.HKD","LU2242652126.USD","BK4534","LU1023059063.AUD","LU0868494617.USD","PBE","BK4588","AMGN","BK4581","IBBQ","LU2112291526.USD","SG9999001440.SGD","LU0320765992.SGD","LU0058720904.USD","PJP","BIB","LU1983299246.USD","IE00BJJMRZ35.SGD","BK4566","BK4139","LU0109394709.USD","BK4533","BBH","IE00BFTCPJ56.SGD","BK4599","LU0289739699.SGD","BK4585","IBB","LU2242646821.SGD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142464","title":"Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR by -42.7% at Week 13 in AMKD with Modest Proteinuria","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142464","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142464?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:02","pubTimestamp":1790082154,"startTime":"0","endTime":"0","summary":"Sept 22 (Reuters) - Vertex Pharmaceuticals Incorporated::*VERTEX ANNOUNCES POSITIVE RESULTS FROM PHASE 2B AMPLIFIED STUDY OF INAXAPLIN IN ADDITIONAL POPULATIONS OF PEOPLE WITH APOL1-MEDIATED KIDNEY DI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nRSD66vtCD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0079474960.USD","LU2362540622.SGD","IBB","BK4533","PBE","LU1674673691.USD","IE00BFTCPJ56.SGD","LU0234570918.USD","LU0823416689.USD","LU0289739699.SGD","LU2237438978.USD","VRTX","LU2468319806.SGD","BK4532","BK4567","LU2362541513.USD","GNMX","LU1093756168.USD","LU2089984988.USD","LU0432979614.USD","LU1035775433.USD","IE00B2B36J28.USD","LU2236285917.USD","LU0256863811.USD","BK4585","IE0002141913.USD","BK4139","IE00B4R5TH58.HKD","IE0009355771.USD","LU0320765992.SGD","IDNA","IE00B894F039.SGD","LU0417517546.SGD","LU2362541273.HKD","LU0889565916.HKD","BIB","IE00BJT1NW94.SGD","BBH","BK4588","IE00B19Z3B42.SGD","IE00B19Z9P08.USD","SG9999001176.SGD","LU0061475181.USD","TBXU","SG9999013999.USD","LU1093756325.SGD","IBBQ","LU2417539215.USD","IE00B19Z9Z06.USD","IE00BZ9MQY76.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142967","title":"Amgen Announces Positive Topline Phase 3 Results for Dazodalibep in Moderate-to-Severe Systemic SjÖGren's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142967","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142967?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:00","pubTimestamp":1790082029,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nFWN45E0FE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","PJP","BBH","BIB","BK4534","LU2468319806.SGD","BK4581","LU1571399168.USD","LU2089984988.USD","IE00BJJMRZ35.SGD","BK4599","BK4588","LU0320765992.SGD","BK4585","IE0002141913.USD","LU0109394709.USD","LU2242646821.SGD","LU0868494617.USD","IE0009355771.USD","LU1023059063.AUD","AMGN","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU1057294990.SGD","LU0058720904.USD","LU0122379950.USD","LU1061106388.HKD","LU1983299246.USD","BK4533","LU0289739699.SGD","IBBQ","PBE","BK4139","BK4566","LU2242652126.USD","LU2112291526.USD","SG9999001440.SGD","TBXU","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142945","title":"Amgen: Dazodalibep Showed Statistically Significant & Clinically Meaningful Improvement in Systemic Disease Activity","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142945","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142945?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:00","pubTimestamp":1790082000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nP8N3Z20GZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","PJP","BBH","BIB","BK4534","LU2468319806.SGD","BK4581","LU1571399168.USD","LU2089984988.USD","IE00BJJMRZ35.SGD","BK4599","BK4588","LU0320765992.SGD","BK4585","IE0002141913.USD","LU0109394709.USD","LU2242646821.SGD","LU0868494617.USD","IE0009355771.USD","LU1023059063.AUD","AMGN","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU1057294990.SGD","LU0058720904.USD","LU0122379950.USD","LU1061106388.HKD","LU1983299246.USD","BK4533","LU0289739699.SGD","IBBQ","PBE","BK4139","BK4566","LU2242652126.USD","LU2112291526.USD","SG9999001440.SGD","TBXU","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142617","title":"Amgen: Phase 3 Oasiz 303 Study of Dazodalibep in Moderate-to-Severe Symptomatic SjÖGren’s Disease Expected to Complete in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142617","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142617?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:00","pubTimestamp":1790082000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nP8N3Z20GZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1057294990.SGD","BK4534","IE00BJJMRZ35.SGD","BBH","PBE","LU0320765992.SGD","BK4599","LU0122379950.USD","LU0889565916.HKD","LU0868494617.USD","BK4585","BIB","LU1983299246.USD","BK4581","SG9999001440.SGD","IE0009355771.USD","IE0002141913.USD","LU0058720904.USD","IBB","AMGN","IE00B2B36J28.USD","IBBQ","LU2112291526.USD","LU1023059063.AUD","IE00B4R5TH58.HKD","BK4588","IE00BFTCPJ56.SGD","BK4566","LU0289739699.SGD","IE00BJT1NW94.SGD","PJP","LU2242646821.SGD","LU2242652126.USD","LU1061106388.HKD","LU2089984988.USD","LU2468319806.SGD","BK4533","TBXU","LU0109394709.USD","LU1571399168.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142210","title":"AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142210","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142210?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:55","pubTimestamp":1790081700,"startTime":"0","endTime":"0","summary":"Daraxonrasib is an important therapeutic advance, but pancreatic cancer is not a simple disease where one successful targeted drug makes additional therapeutic development unnecessary. We believe Ampligen has the potential to complement and extend therapies such as daraxonrasib by helping to overcome the immune biological barriers that have h","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/22/3366375/29489/en/aim-immunotech-highlights-ampligen-s-potential-role-in-the-evolving-pancreatic-cancer-treatment-landscape-following-fda-approval-of-revolution-medicines-daraxonrasib.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANC","IE0009355771.USD","LU0889565916.HKD","PTH","RVMD","IE00B2B36J28.USD","LU0109394709.USD","BBH","BK4139","IE0002141913.USD","LABU","IDNA","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","IE0009354923.USD","IE00BJT1NW94.SGD","BK4588","IE00B4R5TH58.HKD","LU0320765992.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669425861","title":"Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669425861","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669425861?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:50","pubTimestamp":1790081406,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals  said Tuesday that a phase 2b study of inaxaplin to treat patients with APOL1-mediated kidney disease showed a 42.7% protein reduction, and a 17.3% reduction in patients who also have type 2 diabetes.The company said the drug showed a favorable safety profile with no drug-related serious adverse events reported. It said headaches were the most frequent side effect, which affected 7.3% of trial participants.The company said the reduction was measured after 13 weeks of treatment. Vertex said it has finished enrolling patients in a larger Phase 2/3 trial of inaxaplin.Shares of Vertex were up 2.2% pre-bell.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IBB","IE00BZ9MQY76.HKD","IE0009355771.USD","SG9999001176.USD","LU1674673428.USD","IE00B19Z9P08.USD","LU0757428866.USD","IE00B19Z3581.USD","LU2236285917.USD","LU2468319806.SGD","BK4532","LU2089984988.USD","BBH","BK4139","BK4567","LU1559883803.SGD","LU1778281490.HKD","BK4023","TBXU","LU0061475181.USD","IE0002141913.USD","SGXZ57979304.SGD","SG9999013999.USD","IDNA","LU2417539215.USD","IE00BJJMRZ35.SGD","GNMX","PBE","IE0002270589.USD","LU1069344957.HKD","IE00BJT1NW94.SGD","LU1093756325.SGD","BK4533","LU2324357040.USD","LU0566484027.USD","LU2362540622.SGD","LU1035775433.USD","IE00B894F039.SGD","LU0058720904.USD","IBBQ","SG9999001176.SGD","VRTX","IE00B19Z9Z06.USD","LU1674673691.USD","BIB","LU0079474960.USD","BK4588","VERX","LU2362541513.USD","LU1815336091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669144047","title":"Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015","url":"https://stock-news.laohu8.com/highlight/detail?id=2669144047","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669144047?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:30","pubTimestamp":1790080200,"startTime":"0","endTime":"0","summary":"New Preclinical PDAC Package for PRP Shows >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Contrasts Mechanism, Breadth, & Development Role Against Erasca’s Phase 1 ERAS-0015 Datase","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/22/3366329/0/en/propanc-biopharma-highlights-differentiated-prp-pancreatic-cancer-data-versus-emerging-pan-ras-program-eras-0015.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BYTNYN87.SGD","LU0359202008.SGD","IE00B12V2V27.USD","BK4605","LU0109394709.USD","LU1720051017.SGD","PDX","LU2357305700.SGD","TME","ERAS","IE00BYQNZ168.SGD","PPCB","ONX","BK4509","LU1548497426.USD","IDNA","LU2298322129.HKD","LU0269904917.USD","BK4571","BK4585","BK4588","LU2360107325.USD","SG9999011746.SGD","BK4565","IE0002141913.USD","IE0009354923.USD","BK4108","IE00BJT1NW94.SGD","LU1861219969.SGD","LU0509642566.USD","LU1854103824.USD","LU1854104046.USD","ON","BK4531","LU1023057109.AUD","RVMD","LU0724618433.USD","ONG","LU1861220033.SGD","BK4141","BK4535","IE00BFTCPJ56.SGD","LU0320765992.SGD","CANC","01698","BK4139","PTH","BK4512","BK4548","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669144313","title":"Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study","url":"https://stock-news.laohu8.com/highlight/detail?id=2669144313","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669144313?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:15","pubTimestamp":1790079331,"startTime":"0","endTime":"0","summary":"The company states: “Vertex Pharmaceuticals (VRTX) announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-announces-positive-results-from-phase-2b-inaxaplin-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-announces-positive-results-from-phase-2b-inaxaplin-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BFTCPJ56.SGD","LU1430594728.SGD","IE00B19Z3B42.SGD","LU0061475181.USD","LU1585245621.USD","IE00B19Z9Z06.USD","IBBQ","IE0009355771.USD","LU2089984988.USD","LU2237438978.USD","BIB","IE00BJT1NW94.SGD","SG9999013999.USD","LU0432979614.USD","VERX","LU1093756325.SGD","LU0234570918.USD","LU2462157665.USD","IE00B19Z9P08.USD","LU1674673428.USD","LU1815336091.USD","IE0002141913.USD","BK4532","GNMX","LU1778281490.HKD","IE00B4R5TH58.HKD","LU0289739699.SGD","BBH","IE00B2B36J28.USD","LU1035775433.USD","TBXU","IBB","IE00B19Z3581.USD","LU0109394709.USD","SG9999001176.SGD","BK4139","LU0757428866.USD","LU0823416689.USD","LU2236285917.USD","BK4567","BK4023","LU1674673691.USD","BK4588","IDNA","LU1093756168.USD","LU2362540622.SGD","PBE","VRTX","LU0320765992.SGD","LU0256863811.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669177141","title":"Vertex Says Phase 2b Amplified Study Shows Inaxaplin Cuts Proteinuria in APOL1-Mediated Kidney Disease Patients with Modest Proteinuria","url":"https://stock-news.laohu8.com/highlight/detail?id=2669177141","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669177141?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:02","pubTimestamp":1790078577,"startTime":"0","endTime":"0","summary":"Vertex says Phase 2b AMPLIFIED study shows inaxaplin cuts proteinuria in APOL1-mediated kidney disease patients with modest proteinuriaVertex reported positive Phase 2b AMPLIFIED results for inaxaplin","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL8CHhBr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","IE00B19Z9P08.USD","BK4139","IBBQ","LU1093756168.USD","BK4567","IBB","IDNA","IE00BJT1NW94.SGD","SG9999001176.SGD","BIB","LU2462157665.USD","IE00BFTCPJ56.SGD","IE0002270589.USD","LU1069344957.HKD","LU2362541273.HKD","BBH","LU0889565916.HKD","IE00B19Z3B42.SGD","LU1674673691.USD","LU0320765992.SGD","LU0061475181.USD","LU2468319806.SGD","LU1093756325.SGD","SG9999013999.USD","LU0256863811.USD","LU0058720904.USD","BK4585","LU2324357040.USD","LU0432979614.USD","SGXZ57979304.SGD","IE00B19Z3581.USD","LU0079474960.USD","LU2362541513.USD","VRTX","IE0002141913.USD","BK4532","IE0009355771.USD","IE00BZ9MQY76.HKD","LU1035775433.USD","LU2237438978.USD","TBXU","LU1674673428.USD","BK4588","LU0823416689.USD","LU0109394709.USD","IE00B2B36J28.USD","IE00B19Z9Z06.USD","GNMX","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669419861","title":"Vertex Pharmaceuticals Incorporated - Inaxaplin Reduces Uacr by -42.7% at Week 13 in Amkd with Modest Proteinuria","url":"https://stock-news.laohu8.com/highlight/detail?id=2669419861","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669419861?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA6RPXRQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","VRTX","BBH","IBBQ","IE00B2B36J28.USD","PBE","BK4139","IE00BJJMRZ35.SGD","LU0256863811.USD","IE00B19Z3581.USD","LU1674673691.USD","LU2417539215.USD","LU2456880835.USD","IBB","LU1069344957.HKD","LU2236285917.USD","LU2462157665.USD","LU1778281490.HKD","TBXU","IE0002141913.USD","IE0002270589.USD","BK4585","LU0889565916.HKD","LU2362541513.USD","SG9999001176.SGD","SGXZ57979304.SGD","LU2362541273.HKD","IE0009355771.USD","BIB","LU1585245621.USD","LU0823416689.USD","LU2237438978.USD","LU0234570918.USD","GNMX","LU1674673428.USD","IE00B19Z9P08.USD","LU1093756168.USD","IE00B894F039.SGD","LU0289739699.SGD","LU1430594728.SGD","LU0079474960.USD","LU0417517546.SGD","LU2362540622.SGD","LU2468319806.SGD","IE00B4R5TH58.HKD","LU2324357040.USD","IDNA","IE00BJT1NW94.SGD","LU1093756325.SGD","IE00B19Z9Z06.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669419041","title":"Vertex Pharmaceuticals Incorporated - Inaxaplin Generally Safe and Well Tolerated in Both Amkd Cohorts","url":"https://stock-news.laohu8.com/highlight/detail?id=2669419041","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669419041?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA6RPXRQ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0061475181.USD","LU0058720904.USD","LU1585245621.USD","IE00B19Z9Z06.USD","LU2456880835.USD","BK4533","IBBQ","LU2089984988.USD","LU2237438978.USD","IE00BJT1NW94.SGD","BIB","SG9999013999.USD","LU0432979614.USD","LU2362541273.HKD","LU1093756325.SGD","LU0234570918.USD","LU2462157665.USD","IE00B19Z9P08.USD","LU1674673428.USD","LU2324357040.USD","BK4585","IE00BZ9MQY76.HKD","IE0002141913.USD","BK4532","LU1069344957.HKD","GNMX","LU1778281490.HKD","IE00B4R5TH58.HKD","BBH","LU1035775433.USD","TBXU","IBB","LU0109394709.USD","IE0002270589.USD","LU0889565916.HKD","SG9999001176.SGD","SGXZ57979304.SGD","BK4139","LU2417539215.USD","BK4567","BK4588","IDNA","SG9999001176.USD","LU2362541513.USD","PBE","IE00BJJMRZ35.SGD","VRTX","LU0320765992.SGD","LU0256863811.USD","LU0079474960.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669141954","title":"Vertex Announces Positive Results from Phase 2B Amplified Study of Inaxaplin in Additional Populations of People with Apol1-Mediated Kidney Disease (Amkd) and Completion of Enrollment in the Phase 2/3 Amplitude Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669141954","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669141954?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA6RPXRQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","LU2237438978.USD","LU0823416689.USD","IE00B19Z9P08.USD","LU1035775433.USD","LU0109394709.USD","LU1069344957.HKD","LU1093756325.SGD","BK4532","SG9999013999.USD","BIB","IDNA","IE00BZ9MQY76.HKD","LU2236285917.USD","IE00B4R5TH58.HKD","LU0256863811.USD","IE00B19Z3581.USD","BK4585","LU1778281490.HKD","LU1674673691.USD","LU0079474960.USD","IBB","IE0002141913.USD","IE00B2B36J28.USD","PBE","LU1585245621.USD","BK4533","LU0289739699.SGD","IE00BJT1NW94.SGD","LU1674673428.USD","LU2456880835.USD","SG9999001176.USD","IE00B19Z3B42.SGD","IE0002270589.USD","BK4567","SGXZ57979304.SGD","VRTX","IBBQ","LU0058720904.USD","LU0320765992.SGD","LU0432979614.USD","GNMX","TBXU","BK4139","LU0234570918.USD","LU2089984988.USD","BBH","LU0061475181.USD","LU0417517546.SGD","SG9999001176.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669143096","title":"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Invivyd (IVVD) and Humacyte (HUMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669143096","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669143096?lang=en_us&edition=fundamental","pubTime":"2026-09-22 18:10","pubTimestamp":1790071809,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN), Invivyd (IVVD) and Humacyte (HUMA). ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-invivyd-ivvd-and-humacyte-huma-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-invivyd-ivvd-and-humacyte-huma-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","LU0868494617.USD","LU0058720904.USD","LU0109394709.USD","BK4139","IE00B2B36J28.USD","BK4585","LU1057294990.SGD","IE00B4R5TH58.HKD","LU0320765992.SGD","BK4599","LU1983299246.USD","AMGN","SG9999001440.SGD","BK4588","IE0002141913.USD","LU1061106388.HKD","LU2468319806.SGD","TBXU","LU0029874061.USD","BK4533","HCSG","LU1023059063.AUD","LABU","BK4539","IVVD","LU2089984988.USD","PJP","BIB","IBB","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU2242646821.SGD","LU0122379950.USD","LU1571399168.USD","BK4137","BK4566","IBBQ","LU0128526141.USD","IE0009355771.USD","LU0289739699.SGD","BK4563","XLV","XBI","LU0889565916.HKD","PBE","LU2242652126.USD","IE00BJJMRZ35.SGD","BBH","HUMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669511784","title":"Sino Biopharmaceutical Stock Slips 1.4% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2669511784","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669511784?lang=en_us&edition=fundamental","pubTime":"2026-09-22 16:32","pubTimestamp":1790065920,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. slipped 1.4% to 5.84 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.2% to 25087.75.Sino Biopharmaceutical Ltd. closed 32% short of its 52-week high of HK$8.56, which the company reached Sept. 23.The stock underperformed when compared to some of its competitors, as CSPC Pharmaceutical Group Ltd. rose 1.1% and Amgen Inc. remained unchanged.Trading volume totaled 87.2 million shares, compared to the 50-day average of 88.8 million shares.Data source: Dow Jones Market Data, FactSet","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","PBE","LU2089984988.USD","LU2242646821.SGD","IE00B2B36J28.USD","LU0122379950.USD","BK4139","IE00B4R5TH58.HKD","LU0320765992.SGD","BK1589","BIB","IE00BZ08YR35.GBP","LU2468319806.SGD","BK4534","IBB","BK4588","LU0058720904.USD","IE0002141913.USD","LU0289739699.SGD","LU1023059063.AUD","LU1061106388.HKD","LU1571399168.USD","BK4566","IE00BFTCPJ56.SGD","LU1057294990.SGD","BBH","BK1515","IE00BZ08YS42.EUR","IE00BJJMRZ35.SGD","BK4581","PJP","LU2112291526.USD","IE0009355771.USD","BK4585","LU0109394709.USD","IE00BZ08YT58.USD","AMGN","LU0889565916.HKD","BK4533","TBXU","BK4599","SG9999001440.SGD","LU1983299246.USD","HK0000165453.HKD","LU2242652126.USD","BK1521","IBBQ","LU0868494617.USD","IE00BJT1NW94.SGD","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669193392","title":"Nvidia, QIA-Backed Iambic Therapeutics Files for US IPO as Biotech Boom Rolls On","url":"https://stock-news.laohu8.com/highlight/detail?id=2669193392","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669193392?lang=en_us&edition=fundamental","pubTime":"2026-09-22 04:38","pubTimestamp":1790023092,"startTime":"0","endTime":"0","summary":"UPDATE 3-Nvidia, QIA-backed Iambic Therapeutics files for US IPO as biotech boom rolls onSept 21 (Reuters)-Drug developer Iambic Therapeutics, backed by chip giant NvidiaNVDA.Oand Qatar's sovereign we","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nL4N45D1EI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09388","NVDS.UK","3NVD.UK","ABBV","SNPE","07788","AIPI","FDTX","NVDO","JGRO","2NVD.UK","RVMD","USD","TEK","CHAT","BBH","SHOC","CMAG","SNVD.UK","VHT","DIPS","XLF","SOXX","RXL","ESLG","CLSE","ARTY","TFNS","FHLC","JAZZ","NVII","UYG","NVDG","CANC","BAC","NVDA","SOXY","SPTE","PJP","GAMR","VGT","ABFL","07388","CNEQ","SOXQ","LFGY","VT","CHPX","PPH","JDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669619383","title":"Moderna Inc. Stock Climbs 12.3%, Outperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2669619383","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669619383?lang=en_us&edition=fundamental","pubTime":"2026-09-22 04:33","pubTimestamp":1790022780,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Moderna Inc. jumped 12.3% to $172.94 on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index rising 2.3% to 27,122.09 and the Dow Jones Industrial Average rising 0.7% to 52,048.83.Moderna Inc. closed 2.1% short of its 52-week high of $176.66, which the company reached on August 19th.The stock outperformed some of its peers, as Johnson & Johnson fell 0.2% to $269.47, Pfizer Inc. rose 0.3% to $27.74, and Gilead Sciences Inc. rose 0.30% to $150.56.Trading volume totaled 20.9 million, compared to the 50-day average of 17.9 million.Data source: Dow Jones Market Data, FactSet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDI","LU2468319806.SGD","WDNA","LU1778281490.HKD","LU0965509101.SGD","LU1066053197.SGD","IE0002270589.USD","IE00B7SZLL34.SGD","IBBQ","LU1023059063.AUD","BK4548","LU1066051498.USD","LU1430594728.SGD","BMED","IBB","LU1061106388.HKD","LU1839511570.USD","BK4533","LU0109394709.USD","BK4139","BK4532","BK4534","LU0234570918.USD","LU0859254822.USD","LU2089984988.USD","LU0320765992.SGD","LU0058720904.USD","MRNX","IDNA","IE00BSNM7G36.USD","LU1674673428.USD","BK4501","LU0889565916.HKD","SG9999015952.SGD","BK4578","MRNA","LU0122379950.USD","LU1934455194.USD","MRNY","SG9999015986.USD","GNOM","GILD","TMED","LU0861579265.USD","LGHT","LU0289739699.SGD","TBXU","BIB","BBH","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}